Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Brown Financial Advisors

Brown Financial Advisors boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,887 shares of the medical equipment provider’s stock after purchasing an additional 321 shares during the period. Brown Financial Advisors’ holdings in Zimmer Biomet were worth $1,044,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Skylands Capital LLC boosted its position in shares of Zimmer Biomet by 87.5% during the fourth quarter. Skylands Capital LLC now owns 6,986 shares of the medical equipment provider’s stock worth $738,000 after buying an additional 3,261 shares during the period. New World Advisors LLC lifted its stake in Zimmer Biomet by 7.3% during the 4th quarter. New World Advisors LLC now owns 3,813 shares of the medical equipment provider’s stock worth $403,000 after acquiring an additional 260 shares in the last quarter. South Dakota Investment Council boosted its holdings in Zimmer Biomet by 266.6% during the 4th quarter. South Dakota Investment Council now owns 80,886 shares of the medical equipment provider’s stock valued at $8,544,000 after acquiring an additional 58,820 shares during the period. World Equity Group Inc. acquired a new position in Zimmer Biomet in the 4th quarter valued at about $256,000. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Zimmer Biomet by 17.0% during the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 34,447 shares of the medical equipment provider’s stock worth $3,639,000 after purchasing an additional 5,000 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Royal Bank of Canada dropped their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Wells Fargo & Company boosted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Raymond James reduced their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Up 1.1 %

Zimmer Biomet stock opened at $106.00 on Tuesday. The stock has a 50-day simple moving average of $105.85 and a 200-day simple moving average of $107.44. The company has a market capitalization of $21.10 billion, a P/E ratio of 23.82, a PEG ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.